A thermally responsive biopolymer for intra-articular drug delivery

被引:150
作者
Betre, Helawe
Liu, Wenge
Zalutsky, Michael R.
Chilkoti, Ashutosh
Kraus, Virginia B.
Setton, Lori A.
机构
[1] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA
[2] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA
[4] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
关键词
intra-articular; osteoarthritis; drug delivery; sustained release; drug carriers; thermogelling; thermally responsive; elastin-like polypeptide;
D O I
10.1016/j.jconrel.2006.07.022
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Intra-articular drug delivery is the preferred standard for targeting pharmacologic treatment directly to joints to reduce undesirable side effects associated with systemic drug delivery. In this study, a biologically based drug delivery vehicle was designed for intra-articular drug delivery using elastin-like polypeptides (ELPs), a biopolymer composed of repeating pentapeptides that undergo a phase transition to form aggregates above their transition temperature. The ELP drug delivery vehicle was designed to aggregate upon intra-articular injection at 37 degrees C, and form a drug 'depot' that could slowly disaggregate and be cleared from the joint space over time. We evaluated the in vivo biodistribution and joint half-life of radiolabeled ELPs, with and without the ability to aggregate, at physiological temperatures encountered after intra-articular injection in a rat knee. Biodistribution studies revealed that the aggregating ELP had a 25-fold longer half-life in the injected joint than a similar molecular weight protein that remained soluble and did not aggregate. These results suggest that the intra-articular joint delivery of ELP-based fusion proteins may be a viable strategy for the prolonged release of disease-modifying protein drugs for ostcoarthritis and other arthritides. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:175 / 182
页数:8
相关论文
共 49 条
[1]   Liposomal drug formulations - Rationale for development and what we can expect for the future [J].
Allen, TM .
DRUGS, 1998, 56 (05) :747-756
[2]   INHIBITION OF THE PRODUCTION AND EFFECTS OF INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA IN RHEUMATOID-ARTHRITIS [J].
AREND, WP ;
DAYER, JM .
ARTHRITIS AND RHEUMATISM, 1995, 38 (02) :151-160
[3]   Characterization of a genetically engineered elastin-like polypeptide for cartilaginous tissue repair [J].
Betre, H ;
Setton, LA ;
Meyer, DE ;
Chilkoti, A .
BIOMACROMOLECULES, 2002, 3 (05) :910-916
[4]  
BETRE H, 2005, T BIOMED ENG SOC, P528
[5]   In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium [J].
Bozdag, S ;
Çalis, S ;
Kas, HS ;
Ercan, MT ;
Peksoy, I ;
Hincal, AA .
JOURNAL OF MICROENCAPSULATION, 2001, 18 (04) :443-456
[6]   Use of an isolated joint model to detect early changes induced by intra-articular injection of paclitaxel-impregnated polymeric microspheres [J].
Bragdon, B ;
Bertone, AL ;
Hardy, J ;
Simmons, EJ ;
Weisbrode, SE .
JOURNAL OF INVESTIGATIVE SURGERY, 2001, 14 (03) :169-182
[7]   Clinical and radiological effects of anakinra in patients with rheumatoid arthritis [J].
Bresnihan, B ;
Cobby, M .
RHEUMATOLOGY, 2003, 42 :22-28
[8]   Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery [J].
Bromberg, LE ;
Ron, ES .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 31 (03) :197-221
[9]  
Brown KE, 1998, ARTHRITIS RHEUM, V41, P2185, DOI 10.1002/1529-0131(199812)41:12<2185::AID-ART13>3.0.CO
[10]  
2-C